Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.52 |
| ▸ | CRBN | Q96SW2 | 11/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 9/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | IKZF2 | Q9UKS7 | 3/20 | 0.43 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29337565 | 1.00 | IRAK4 (0.52) | IRAK4CRBNMAPTDDB1LRRK2 | |
| SCHEMBL21026009 | 0.88 | IRAK4 (0.62) | IRAK4CRBNMAPTDDB1LRRK2 | |
| SCHEMBL21025800 | 0.88 | IRAK4 (0.62) | IRAK4CRBNMAPTDDB1LRRK2 | |
| SCHEMBL29337546 | 0.85 | MAPT (0.46) | IRAK4CRBNMAPTDDB1LRRK2 | |
| SCHEMBL30817904 | 0.82 | CRBN (0.53) | CRBNMAPTDDB1LRRK2ALDH1A1 | |
| SCHEMBL29336480 | 0.79 | CRBN (0.58) | IRAK4CRBNMAPTDDB1LRRK2 | |
| SCHEMBL28719101 | 0.78 | CRBN (0.53) | CRBNMAPTDDB1LRRK2ALDH1A1 | |
| SCHEMBL25159874 | 0.78 | CRBN (0.60) | CRBNMAPTDDB1LRRK2ALDH1A1 | |
| SCHEMBL20985423 | 0.78 | CRBN (0.60) | CRBNMAPTDDB1LRRK2ALDH1A1 | |
| SCHEMBL20294594 | 0.78 | CRBN (0.60) | IRAK4CRBNMAPTDDB1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | IRAK1, IRAK4, IRAK2 | IRAK4 2/4885CRBN 4/4885MAPT 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.